Publicaciones (170) Publicaciones de JAVIER PUENTE VÁZQUEZ

2024

  1. Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study

    The Lancet Oncology, Vol. 25, Núm. 1, pp. 46-61

  2. Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study

    The Lancet Oncology, Vol. 25, Núm. 1, pp. 29-45

  3. CRISPR/Cas9 screenings unearth protein arginine methyltransferase 7 as a novel essential gene in prostate cancer metastasis

    Cancer Letters, Vol. 588

  4. Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non–small cell lung cancer

    Lung Cancer, Vol. 192

  5. Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study

    European Urology, Vol. 86, Núm. 1, pp. 4-9

  6. Criteria and indicators to evaluate quality of care in genitourinary tumour boards

    Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1639-1646

  7. Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial

    Clinical and Translational Oncology, Vol. 26, Núm. 6, pp. 1532-1538

  8. Impact of COVID-19 infection on genitourinary cancer management. SOGUG-COVID-19: A spanish, multicenter, observational study

    Clinical and Translational Oncology

  9. Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study

    ESMO Open, Vol. 9, Núm. 9

  10. Management of Adverse Reactions Related to Lenvatinib Plus Pembrolizumab Treatment Among Patients With Renal Cell Carcinoma

    Clinical Genitourinary Cancer

  11. Molecularly Defined Renal Carcinomas

    Kidney Cancer, Vol. 8, Núm. 1, pp. 31-44

  12. Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1)

    British Journal of Cancer, Vol. 130, Núm. 3, pp. 434-441

  13. Prognostic Implications of Blood Immune-Cell Composition in Metastatic Castration-Resistant Prostate Cancer

    Cancers, Vol. 16, Núm. 14

  14. Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study

    European urology oncology, Vol. 7, Núm. 3, pp. 447-455

  15. Real-world treatment patterns, survival outcomes, and health care resource utilization for locally advanced or metastatic urothelial carcinoma in Spain

    Clinical and Translational Oncology

2023

  1. A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide

    Prostate, Vol. 83, Núm. 4, pp. 376-384

  2. A multidisciplinary consensus statement on the optimal pharmacological treatment for metastatic hormone-sensitive prostate cancer

    Actas Urologicas Espanolas, Vol. 47, Núm. 2, pp. 111-126

  3. Abiraterone in low-volume metastatic hormone-sensitive prostate cancer. Authors’ reply

    Actas Urologicas Espanolas

  4. Characterization and Management of Adverse Reactions From the CLEAR Study in Advanced Renal Cell Carcinoma Treated With Lenvatinib Plus Pembrolizumab

    Oncologist, Vol. 28, Núm. 6, pp. 501-509

  5. Darolutamide in Spanish patients with nonmetastatic castration-resistant prostate cancer: ARAMIS subgroup analysis

    Future Oncology, Vol. 19, Núm. 12, pp. 819-828